NRAS and neoplasm: Although NRAS mutation is often associated with an increased mutational tumor burden, with a potential benefit from treatment with a checkpoint-inhibitor, Kirchberger et al. reported similar result for checkpoint inhibitors in NRAS-mutant and WT patients, with a reduced survival in NRAS-mutant ones [19].